DEG works alongside Finnegan’s stellar trial team who secures patent protection for Relistor Tablets until March 2031
The U.S. District Court of New Jersey upheld the validity of Bausch Health Companies Inc.’s patent protecting Relistor (methylnaltrexone bromide) tablets and determined Actavis’ infringement of the patent for opioid-induced constipation in patients with chronic non-cancer pain. The case is Bausch Health Cos. Inc. et al., v. Actavis Laboratories FL Inc., case number 16-cv-9038, in the U.S. District Court for the District of New Jersey.